Bronchial asthma is a chronic respiratory disease characterized by airway inflammation and hyperresponsiveness. Despite the availability of conventional therapies, a subset of patients with severe asthma remains uncontrolled and experiences frequent exacerbations. In recent years, the emergence of biological drugs has revolutionized the management of severe asthma by targeting specific inflammatory pathways. This study aims to provide an overview of the use of biologic drugs in patients with bronchial asthma. Subsequently, it explores the efficacy of different biologic agents, including monoclonal antibodies targeting immunoglobulin E (IgE), interleukin-5 (IL-5), and IL-4/IL-13 pathways. Furthermore, this review examines the clinical evidence supporting the use of biologic drugs in treating of severe asthma. This study was done to provide: The biological drugs approved by the FDA in the treatment of bronchial Asthma, The efficacy of some biological drugs in the treatment of bronchial asthma and the safety profile of these drugs. This study is a review of articles done by meta-analysis within the last ten years from 2013 to 2023 concerning the use of biological drugs in the treatment of bronchial asthma.